Updating the approach to Crohn's disease

Stephen B. Hanauer

doi:10.1080/21548331.1999.11443892

Updating the approach to Crohn's disease

Stephen B. Hanauer^*

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Recognizing clinical and pathologic scenarios, rather than ordering definitive tests, is still the basis for diagnosis of Crohn's disease. Steroids, salicylates, immunomodulating agents, and surgery remain the focus of treatment. The advent of infliximab, however, offers a new therapeutic option for patients with refractory disease.

Original language	English (US)
Pages (from-to)	77-94
Number of pages	18
Journal	Hospital Practice
Volume	34
Issue number	8
DOIs	https://doi.org/10.1080/21548331.1999.11443892
State	Published - Aug 15 1999

ASJC Scopus subject areas

General Medicine

Access to Document

10.1080/21548331.1999.11443892

Cite this

@article{e0105af0d5744763b832242a0b877642,

title = "Updating the approach to Crohn's disease",

abstract = "Recognizing clinical and pathologic scenarios, rather than ordering definitive tests, is still the basis for diagnosis of Crohn's disease. Steroids, salicylates, immunomodulating agents, and surgery remain the focus of treatment. The advent of infliximab, however, offers a new therapeutic option for patients with refractory disease.",

author = "Hanauer, {Stephen B.}",

year = "1999",

month = aug,

day = "15",

doi = "10.1080/21548331.1999.11443892",

language = "English (US)",

volume = "34",

pages = "77--94",

journal = "Hospital Practice",

issn = "8750-2836",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - Updating the approach to Crohn's disease

AU - Hanauer, Stephen B.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - Recognizing clinical and pathologic scenarios, rather than ordering definitive tests, is still the basis for diagnosis of Crohn's disease. Steroids, salicylates, immunomodulating agents, and surgery remain the focus of treatment. The advent of infliximab, however, offers a new therapeutic option for patients with refractory disease.

AB - Recognizing clinical and pathologic scenarios, rather than ordering definitive tests, is still the basis for diagnosis of Crohn's disease. Steroids, salicylates, immunomodulating agents, and surgery remain the focus of treatment. The advent of infliximab, however, offers a new therapeutic option for patients with refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=0033567206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033567206&partnerID=8YFLogxK

U2 - 10.1080/21548331.1999.11443892

DO - 10.1080/21548331.1999.11443892

M3 - Article

C2 - 10459364

AN - SCOPUS:0033567206

SN - 8750-2836

VL - 34

SP - 77

EP - 94

JO - Hospital Practice

JF - Hospital Practice

IS - 8

ER -

Updating the approach to Crohn's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this